Next Article in Journal
Resveratrol Targets Sphingolipid Metabolism and BCR-ABL in Ph+ Acute Lymphoblastic Leukemia to Induce Growth Inhibiton
Previous Article in Journal
GIS in the History Classroom: Displaying the Walls of Elvas and Badajoz through the Use of Google Earth
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

Pre-Clinical and Clinical Study Rules for Herbal Medicines †

Faculty of Pharmacy, Eastern Mediterranean University, North Cyprus via Mersin-10, 99628 Famagusta, Turkey
Presented at the 3rd International conference on Natural Products for Cancer Prevention and Therapy, Kayseri, Turkey, 18–20 December 2019.
Proceedings 2019, 40(1), 1; https://doi.org/10.3390/proceedings2019040001
Published: 25 December 2019

Abstract

Herbal medicines consist of many different type of active ingredients obtained from medicinal plants. The amounts of compounds may be changeable with the environmental, harvesting, draying, storage conditions and process of production as well. In the therapy, efficacy, safety and quality are the main properties for both synthetic and natural medicines. Standardized extracts contain certain amount of active ingredient(s) without toxic impurities. Preventive, prophylactic, and curative activities of the standardized extracts are related with their variable chemical constitution. Because of many active ingredients within the herbal products, their toxicity assays, dose-response relationships and clinical trial tests are difficult to follow and not clear. In this review, the impotency of the pre-clinical studies on the herbal products, their standardization and trues/falses/challenges in their clinical trials will be investigated.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Koşar, M. Pre-Clinical and Clinical Study Rules for Herbal Medicines. Proceedings 2019, 40, 1. https://doi.org/10.3390/proceedings2019040001

AMA Style

Koşar M. Pre-Clinical and Clinical Study Rules for Herbal Medicines. Proceedings. 2019; 40(1):1. https://doi.org/10.3390/proceedings2019040001

Chicago/Turabian Style

Koşar, Müberra. 2019. "Pre-Clinical and Clinical Study Rules for Herbal Medicines" Proceedings 40, no. 1: 1. https://doi.org/10.3390/proceedings2019040001

APA Style

Koşar, M. (2019). Pre-Clinical and Clinical Study Rules for Herbal Medicines. Proceedings, 40(1), 1. https://doi.org/10.3390/proceedings2019040001

Article Metrics

Back to TopTop